InDex Pharmaceuticals Holding AB (publ) interim report January – June 2023
License agreement signed with Viatris Japan
License agreement signed with Viatris Japan
August 22, 2023 – InDex Pharmaceuticals Holding AB (publ) today announced that the positive results from the pharmacokinetic (PK) study with cobitolimod in patients with moderate to severe ulcerative colitis will be presented at one of the leading gastroenterology conferences, the United European Gastroenterology Week (UEGW). The abstract was selected as one of the best abstracts for poster presentation and is therefore also chosen to be presented orally in one of the moderated poster sessions.
August 2, 2023 – InDex Pharmaceuticals Holding AB (publ) today announced that a new formulation patent for the drug candidate cobitolimod has been granted by the European Patent Office. The patent provides protection of the enema formulation of cobitolimod, that is currently under evaluation in the ongoing phase III program CONCLUDE.
May 31, 2023 – InDex Pharmaceuticals Holding AB (publ) will hold an investor call in light of today’s press release announcing the company’s license agreement. The investor call will take place on June 1, 2023 at 15:00 CET via MS Teams.
May 31, 2023 – InDex Pharmaceuticals Holding AB (publ) (“InDex”) today announced that a license agreement has been signed with Viatris Pharmaceutical Japan Inc. (“Viatris Japan”) to register and commercialize cobitolimod in Japan for the treatment of ulcerative colitis. Cobitolimod is a TLR9 agonist which is being evaluated in the global phase III program CONCLUDE, as a novel treatment for moderate to severe ulcerative colitis. The agreement including milestones is worth up to USD$50m, excluding royalties.
May 24, 2023 – The annual general meeting in InDex Pharmaceuticals Holding AB (publ) was held on Wednesday 24 May 2023. The following resolutions, amongst others, were passed at the general meeting.
Positive results from pharmacokinetic study with cobitolimod
April 26, 2023 – InDex Pharmaceuticals Holding AB (publ) invites investors, analysts and media to attend a live business update during which Jenny Sundqvist, CEO, and the InDex Pharmaceuticals leadership team will share insights and updates on the company’s mission to improve the lives of patients suffering from immunological diseases. Focus will be on the ongoing phase III program CONCLUDE with the company’s lead asset, cobitolimod – a potential new medication for patients with ulcerative colitis.
N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the annual general meeting. In case of any discrepancies between the Swedish and English language versions, the Swedish version shall prevail.
April 19 2023 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820 (the “Company”), are hereby summoned to the Annual General Meeting on Wednesday May 24, 2023 at 17.00 (CET) at Setterwalls Advokatbyrå’s offices at Sturegatan 10 in Stockholm. Registration for the meeting commences at 16.30 (CET).
April 12, 2023 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2022. The Annual Report is attached as a PDF and is available on the company’s website, https://www.indexpharma.com/en/financial-reports/.
March 15, 2023 – InDex Pharmaceuticals Holding AB (publ) today announced positive results from a pharmacokinetic (PK) study with cobitolimod in patients with moderate to severe ulcerative colitis. The systemic uptake was limited both for patients with active disease and in clinical remission. For the first time patients have been treated with doses of 500 mg, and in line with previous studies cobitolimod was well tolerated.
February 27, 2023 – InDex Pharmaceuticals Holding AB (publ) today announced that the company will attend the annual congress of the European Crohn’s and Colitis Organisation (ECCO), March 1-4, 2023 in Copenhagen. ECCO is the largest forum for specialists in inflammatory bowel disease globally.
February 14, 2023 – InDex Pharmaceuticals Holding AB (publ) is today making a presentation with CEO Jenny Sundqvist available in light of the press release issued January 27, 2023 regarding the updated timeline of the CONCLUDE program.
January 27, 2023 – InDex Pharmaceuticals Holding AB (publ) today announced an update in the timing of the dose selection in the ongoing phase III study CONCLUDE with the drug candidate cobitolimod. The outcome of the dose selection is expected to be available Q4 2023. At that point in time InDex will have finalised the assessments of consequences on the overall development timeline including topline results in CONCLUDE.
The Board has appointed Jenny Sundqvist as new CEO
October 26, 2022 – InDex Pharmaceuticals Holding AB (publ) today announced the composition of the Nomination Committee for the 2023 Annual General Meeting. The responsibility of the Nomination Committee is to present to the 2023 Annual General Meeting proposals regarding election of the Chairman of the Board and other members of the Board, fees and any other remuneration to the members of the Board as well as election and remuneration of the auditors.
October 10, 2022 – InDex Pharmaceuticals Holding AB (publ) today announced that the Board of Directors has named Jenny Sundqvist as new CEO. Jenny comes from a position as Chief Commercial Officer at Isofol Medical AB and has broad experience from leading positions within the pharmaceutical industry. Johan Giléus, who has been acting CEO since April 2022, will continue as CFO in the company.
October 5, 2022 – InDex Pharmaceuticals Holding AB (publ) today announced that the company will be exhibiting at the United European Gastroenterology Week (UEGW) October 8-11, 2022 in Vienna. UEGW is the largest scientific meeting for gastroenterologists in Europe.
PMDA supports InDex’s development plan for cobitolimod in Japan
16 August, 2022 – InDex Pharmaceuticals Holding AB (publ) today announced that the company has received positive feedback from the Japanese regulatory authority, the Pharmaceuticals and Medical Devices Agency (PMDA), regarding the clinical development plan for a future marketing authorization application for the company’s TLR9 agonist cobitolimod, for the treatment of moderate to severe left-sided ulcerative colitis. The PMDA has accepted enrolment of Japanese ulcerative colitis patients in the second global phase III induction study, without performing specific Japanese studies prior to study start.
July 13, 2022 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the European Patent Office (EPO). The patent provides additional protection for the use of cobitolimod in the treatment of inflammatory bowel disease.
June 1, 2022 – The annual general meeting in InDex Pharmaceuticals Holding AB (publ) was held on Wednesday 1 June 2022. The following resolutions, amongst others, were passed at the general meeting:
Full focus on the phase III study CONCLUDE with cobitolimod
May 12, 2022 – InDex Pharmaceuticals Holding AB (publ) today announced that the company will be exhibiting at the Digestive Disease Week (DDW) May 21-24, 2022 in San Diego. DDW is the world’s premier meeting for healthcare professionals, researchers and industry in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.
May 2, 2022 – InDex Pharmaceuticals Holding AB (publ) today announced that the company has appointed Eva Arlander as Chief Development Officer. Eva will also be part of the management team, together with acting Chief Executive Officer and Chief Financial Officer Johan Giléus, Chief Medical Officer Anders Bröijersén and Chief Scientific Officer Charlotte Admyre.
28 April 2022 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820 (the “Company”), are hereby summoned to the Annual General Meeting on Wednesday 1 June, 2022 at 17.00 (CET) through advance voting. Attendance at the meeting is only possible via postal ballot.
April 11, 2022 – InDex Pharmaceuticals Holding AB (publ) today announced that after more than seven years as CEO, Peter Zerhouni has decided to leave his position. The company’s CFO Johan Giléus has been appointed acting CEO while a new CEO is being recruited, and he will also continue as CFO.
April 8, 2022 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2021. The Annual Report is attached as a PDF and is available on the company’s website, https://www.indexpharma.com/en/financial-reports/.
March 13, 2022 – InDex Pharmaceuticals Holding AB (publ) is planning for self-commercialisation of the drug candidate cobitolimod in the US with strategic collaborations in other regions. Launch is expected in 2027, with the potential for annual sales to reach more than USD 1 billion, in moderate to severe left-sided ulcerative colitis. An in-depth presentation of the strategy and market potential, together with the execution of the phase III study CONCLUDE with cobitolimod will be provided at InDex’s Capital Markets Day, tomorrow March 14, 15.00-17.00 CET.
March 7, 2022 – InDex Pharmaceuticals Holding AB (publ) invites investors, analysts and media to a Capital Markets Day on March 14, 2022. The Capital Markets Day will be held in Krügersalen at Kapitel 8, Tändstickspalatset, Västra Trädgårdsgatan 15 in Stockholm. The presentations will start at 15.00 CET with registration from 14.30 CET.
First patient enrolled in the phase III study CONCLUDE
February 15, 2022 – InDex Pharmaceuticals Holding AB (publ) invites investors, analysts and media to a Capital Markets Day on March 14, 2022. The Capital Markets Day will be held in Krügersalen at Kapitel 8, Tändstickspalatset, Västra Trädgårdsgatan 15 in Stockholm. The presentations will start at 15.00 CET with registration from 14.30 CET.
February 13, 2022 – InDex Pharmaceuticals Holding AB (publ) today announced that Chief Operating Officer Pernilla Sandwall has decided to leave the company to become CEO of WntResearch. She will continue in her current role until the end of April. The process to recruit her successor will be initiated immediately.
December 8, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that the first patient has been enrolled in the clinical pharmacokinetic study (PK study) with cobitolimod. The purpose of the study is to evaluate the systemic uptake of cobitolimod in local treatment of colonic inflammation.
November 24, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that the first patient has been enrolled in the pivotal phase III study CONCLUDE. The study will evaluate the efficacy and safety of the first-in-class TLR9 agonist cobitolimod as a novel treatment for patients with moderate to severe left-sided ulcerative colitis.
Ready to initiate patient recruitment in phase III study CONCLUDE
November 16, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the Canadian Intellectual Property Office (CIPO). The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy.
November 10, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced the composition of the Nomination Committee for the 2022 Annual General Meeting. The responsibility of the Nomination Committee is to present to the 2022 Annual General Meeting proposals regarding election of the Chairman of the Board and other members of the Board, fees and any other remuneration to the members of the Board as well as election and remuneration of the auditors.
November 9, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the United States Patent and Trademark Office (USPTO). The patent provides protection for the use of certain dosage regimens of cobitolimod for treating inflammatory bowel disease, including the 250 mg dose which was successful in the phase IIb study CONDUCT.
November 8, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Life Science Day 2021 on November 11 at 09.00 CET. The presentation will be livestreamed and can be followed at https://www.redeye.se/events/815899/redeye-life-science-day-2021.
First regulatory approvals to start the phase III study CONCLUDE
August 24, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that the U.S. Food and Drug Administration (FDA) has given clearance to start the phase III clinical study CONCLUDE in the United States. The study will evaluate the efficacy and safety of the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis.
August 23, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that two new employees have been appointed in the clinical development organisation in preparation of the start of the phase III study CONCLUDE with cobitolimod.
August 19, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that the company will conduct a clinical pharmacokinetic study (PK study) with cobitolimod in Sweden. The Swedish Medical Products Agency has given approval to start the study.
July 21, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that the Swedish Medical Products Agency (MPA) has given approval to start the phase III clinical study CONCLUDE in Sweden. The study will evaluate the efficacy and safety of the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis.
June 3, 2021 – The annual general meeting in InDex Pharmaceuticals Holding AB (publ) was held on Thursday June 3, 2021. The following resolutions, amongst others, were passed at the general meeting:
May 31, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that patient recruitment for the phase III study CONCLUDE is planned to initiate after the summer. The study will evaluate the efficacy and safety of the drug candidate cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis.
May 27, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Growth Day 2021 on June 2 at 8.50 CET. The presentation will be livestreamed and can be followed at https://www.redeye.se/events/808637/redeye-growth-day-2021.
The crucial pieces of the puzzle in place for the start of phase III
May 4, 2021 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820 (the “Company”), are hereby summoned to the Annual General Meeting on Thursday 3 June, 2021 at 17.00 (CET) through advance voting. Attendance at the meeting is only possible via postal ballot.
April 23, 2021 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2020. The Annual Report is attached as a PDF and is available on the company’s website, https://www.indexpharma.com/en/financial-reports-and-presentations/.
April 7, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that a patent covering 19 compounds from the company’s DIMS platform has been granted by the European Patent Office.
March 30, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that the company has entered an agreement for services with global clinical research organization (CRO) Parexel Biotech for the phase III study CONCLUDE. The study will evaluate the efficacy and safety of the drug candidate cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis.
March 15, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced changes in the composition of the Nomination Committee for the 2021 Annual General Meeting due to changes in the ownership structure of the company.
March 12, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that the list of shareholders on the homepage has been updated with information as of February 26, 2021.
March 10, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Barclays Global Healthcare Conference on Thursday March 11, 2021 and at Carnegie Nordic Virtual Healthcare Seminar on Friday March 12, 2021, both at 13:30 CET.
Financing secured for phase III development of cobitolimod
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, CANADA, HONG KONG, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES.
9 February 2021 – The subscription period of the rights issue in InDex Pharmaceuticals Holding AB (publ) (”InDex” or the “Company”) ended on 5 February 2021. The subscription ratio in the rights issue amounted to 152.6 percent. Guarantee commitments made in connection with the rights issue will thus not be utilized. InDex will, through the rights issue, receive approximately SEK 533 million before deduction of costs related to the transaction.
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES.
21 January 2021 – The board of directors of InDex Pharmaceuticals Holding AB (publ) (”InDex” or the “Company”) has prepared a prospectus in connection with the rights issue of approximately MSEK 533 announced through a press release on 14 January 2021 (the “Rights Issue”). The prospectus has today been approved and registered by the Swedish Financial Supervisory Authority and is available on the Company’s website.
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES.
14 January 2021 – The board of directors of InDex Pharmaceuticals Holding AB (publ) (”InDex” or the ”Company”) has, with the support of the authorisation from the extraordinary general meeting held on 12 January 2021, resolved on a rights issue of approximately 444 million shares at a subscription price of SEK 1.20 per share (the “Rights Issue”). The Rights Issue is fully covered by subscription undertakings and guarantee commitments from existing shareholders and new investors, including amongst others HBM Healthcare Investments, Handelsbanken Funds, Linc and The Fourth Swedish National Pension Fund. At full subscription in the Rights Issue the Company will receive approximately MSEK 533 before deduction of costs related to the transaction.
12 January 2021 – The Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ) was held on 12 January 2021 at the offices of Setterwalls Advokatbyrå at Sturegatan 10, Stockholm. Attendance at the meeting was solely possible via postal voting. The following resolutions were passed at the general meeting.
December 9, 2020 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820, are hereby summoned to an Extraordinary General Meeting on Tuesday 12 January, 2021 at 10.00 p.m. (CET) through advance voting. Attendance at the meeting is only possible via postal ballot.
December 3, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced the composition of the Nomination Committee for the 2021 Annual General Meeting. The responsibility of the Nomination Committee is to present to the 2021 Annual General Meeting proposals regarding election of the Chairman of the Board and other members of the Board, fees and any other remuneration to the members of the Board as well as election and remuneration of the auditors.
November 26, 2020 – InDex Pharmaceuticals Holding AB (publ) (”InDex”) today announced that the company will host a virtual R&D day on Tuesday December 8, 2020 for investors, analysts and media.
Phase III plan laid out
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES.
November 25, 2020 – InDex Pharmaceuticals Holding AB (publ) (“InDex” or the “Company”) (Nasdaq First North Growth Market: INDEX) intends to carry out a fully guaranteed rights issue of approximately SEK 500 million with preferential rights for the Company’s existing shareholders (the “Rights Issue”). The Company’s Board of Directors intends to propose that an extraordinary general meeting to be held in January 2021 (the “EGM”) would authorize the Board of Directors to resolve on the Rights Issue and the terms thereof. The net proceeds from the contemplated Rights Issue are mainly intended to be used to fund the important initial induction study in a sequential phase III program in moderate to severe left-sided ulcerative colitis for the Company’s lead drug candidate, cobitolimod. A notice to the EGM will be announced through a separate press release at a later date.
November 24, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Life Science Day at 13:50 CET on November 26. The presentation will be livestreamed and can be followed at https://www.redeye.se/events/792760/redeye-life-science-day, where the presentation also will be available afterwards.
October 6, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that the results of the CONDUCT study have been published in the high-impact medical journal The Lancet Gastroenterology and Hepatology. CONDUCT was a phase IIb dose optimisation study, evaluating the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis. The study met the primary endpoint and cobitolimod demonstrated an outstanding combination of efficacy and safety.
Focus on phase III preparations
August 24, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that the results of the CONDUCT study will be presented orally at two leading gastroenterology conferences; the United European Gastroenterology Week (UEGW) and the American College of Gastroenterology (ACG) Annual Scientific Meeting. CONDUCT was a phase IIb dose optimisation study, evaluating the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis. The study met the primary endpoint with an outstanding combination of efficacy and safety.
May 26, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Growth Day 2020 on June 2 at 15.50 CET. The presentation will be livestreamed and can be followed at https://www.redeye.se/live/growth-day-2020.
FDA and EMA endorse the advancement of cobitolimod into phase III studies
April 20, 2020 – The annual general meeting in InDex Pharmaceuticals Holding AB (publ) was held on Monday 20 April 2020 at Setterwalls Advokatbyrå’s offices at Sturegatan 10 in Stockholm, Sweden. The following resolutions, amongst others, were passed at the general meeting:
April 16, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that the company has received positive responses from FDA and EMA regarding phase III development of the company’s TLR9 agonist cobitolimod, for the treatment of moderate to severe ulcerative colitis. The company is continuing its phase III preparations, including efforts to secure financing.
April 8, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that the company plans to hold its Annual General Meeting 2020 as scheduled at 5.00 pm on April 20, 2020, but takes precautionary measures.
· Due to the risk for spread of infection InDex plans to limit the scope of the Annual General Meeting and the presence of the Board of Directors and Management.
· There will be no presentation by the CEO at the Annual General Meeting. InDex plans to provide update via other channels close to the Annual General Meeting.
· No food or refreshments will be served.
· The number of attendees will be limited in accordance with the restrictions in force at the time of the Annual General Meeting.
31 mars 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that SEK 2.0 million has been granted from Sweden’s innovation agency Vinnova to develop new, more effective and safer treatments for inflammatory diseases.
March 30, 2020 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2019. The Annual Report (in the Swedish language) is attached as a PDF and is available on the company’s website, https://www.indexpharma.com/en/category/annual-reports/.
N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the annual general meeting. In case of any discrepancies between the Swedish and English language versions, the Swedish version shall prevail.
March 19, 2020 – The shareholders in InDex Pharmaceuticals Holding AB, reg. no. 559067-6820 (the “Company”), are hereby given notice to attend the annual general meeting at 5 p.m. on Monday 20 April 2020 at Setterwalls Advokatbyrå’s offices at Sturegatan 10 in Stockholm. Registration for the meeting commences at 4.30 p.m.
February 25, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced the publication of scientific data on the mechanism of action of cobitolimod, the company’s lead drug candidate in development for the treatment of moderate to severe ulcerative colitis. The paper, published in the peer-reviewed Journal of Crohns and Colitis (JCC), shows that the Toll-like receptor 9 (TLR9) agonist cobitolimod can modulate the immune system in ulcerative colitis by balancing the mucosal Th17/Treg cell response. The publication has also been highlighted in the journal podcast.
Cobitolimod’s outstanding combination of efficacy and safety confirmed in in-depth analysis
February 19, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced the conclusions from in-depth analysis of the complete data set from the phase IIb dose optimisation study CONDUCT, evaluating the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis. The analysis confirms that the highest dose tested, which met the primary endpoint of the study, demonstrates an outstanding combination of efficacy and safety.
Outstanding combination of efficacy and safety in the CONDUCT study
November 18, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Life Science Day at ROOTS@Downtown Camper by Scandic, Drottninggatan 28 in Stockholm at 08:35 CET and at Avanza Börsdag at Operaterrassen, Karl XII:s torg in Stockholm at 11:15 CET on November 19. Both presentations will be livestreamed.
November 1, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced the composition of the Nomination Committee for the 2020 Annual General Meeting. The responsibility of the Nomination Committee is to present to the 2020 Annual General Meeting proposals regarding election of the Chairman of the Board and other members of the Board, fees and any other remuneration to the members of the Board as well as election and remuneration of the auditors.
October 28, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that the list of shareholders has been updated on the homepage with information as of October 18, 2019.
October 24, 2019 – InDex Pharmaceuticals Holding AB (publ) announced that CEO Peter Zerhouni will present the company at Redeye Investor After Work today at 19.30 CET at Scandic Rubinen, Kungsportsavenyen 24, in Gothenburg. The presentation will be livestreamed and can be followed at https://www.redeye.se/live/inv-aw-gbg-24-10.
October 9, 2019 – An Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ) (“InDex” or the “Company”) took place on Wednesday, October 9, 2019 in the Company´s premises at Tomtebodavägen 23a in Stockholm, Sweden. At the Extraordinary General Meeting the following was resolved.
September 19, 2019 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820, are hereby summoned to an Extraordinary General Meeting on Wednesday October 9, 2019 at 4:00 p.m. (CET) at the Company´s premises, Tomtebodavägen 23a in Stockholm, Sweden. Registration for the meeting begins at 3:30 p.m.
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA, THE “UNITED STATES”), AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.
September 19, 2019 – The Board of Directors of InDex Pharmaceuticals Holding AB (“InDex” or the “Company”) (Nasdaq First North Growth Market: INDEX) has, as communicated in the Company’s press release earlier today, resolved to issue a maximum of 20,000,000 shares (the “New Shares”), where a maximum of 13,756,255 shares are issued based on the authorization granted by InDex’s annual general meeting on 6 May 2019 and a maximum of 6,243,745 shares are issued subject to the subsequent approval of the extraordinary general meeting (together “Directed Share Issue”). The subscription price in the Directed Share Issue is SEK 6.98 per share and corresponds to the closing price on Nasdaq First North Growth Market on 19 September 2019. The subscription price in the Directed Share Issue has been determined through an accelerated book building procedure (the “Book building”). Through the Directed Share Issue, InDex will receive proceeds amounting to approximately SEK 140 million before transaction related costs. Investors in the Directed Share Issue are a wide range of Swedish and international investors including reputable new investors such as the Fourth Swedish National Pension Fund as well as current shareholders such as Stiftelsen Industrifonden and Bengt Julander (through Linc AB).
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA, THE “UNITED STATES”), AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.
September 19, 2019 – InDex Pharmaceuticals Holding AB (publ) (“InDex” or the “Company”) (Nasdaq First North Growth Market: INDEX) hereby announces its intention of a placement of shares corresponding to up to approximately 30 percent of the total number of shares in the Company through issuance of new shares directed to Swedish and international institutional investors. The directed share issue is intended to be carried out, in part based on the authorization granted by the annual general meeting held on 6 May, 2019, and in part subject to the approval of an extraordinary general meeting (together the “Directed Share Issue”). InDex has engaged Carnegie Investment Bank AB (publ) and Pareto Securities AB to act as Joint Bookrunners (together the “Joint Bookrunners”) in connection with the Directed Share Issue.
September 5, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that the list of shareholders has been updated on the homepage with information as of August 30, 2019.
· Outstanding combination of efficacy and safety
· 15% delta vs. placebo for clinical remission
August 27, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced positive top line results from the dose optimisation study CONDUCT, which is evaluating cobitolimod for the treatment of moderate to severe ulcerative colitis. The study met the primary endpoint of clinical remission, demonstrating a superior efficacy of 15% (delta) in patients receiving the highest dose of cobitolimod compared to placebo. Cobitolimod was well tolerated at all dose levels and no differences in the safety profile were observed compared to placebo.
Last patient enrolled in the CONDUCT study
June 26, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the European Patent Office. The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy.
June 26, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that patient enrolment was completed in the dose optimisation study CONDUCT, which is evaluating cobitolimod for the treatment of moderate to severe ulcerative colitis. Top line results are expected to be available in 8-10 weeks.
June 3, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Growth Day at Haymarket by Scandic, Hötorget 13-15, in Stockholm on June 10 at 14.40 CET. The presentation will be livestreamed and can be followed at http://www.redeye.se/live/redeye-growth-day-19.
May 23, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at the Introduce Investor Days at Haymarket by Scandic in Stockholm on May 27 at 9.30 CET.
May 6, 2019 – The Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) took place on Monday, May 6, 2019 in the company´s premises at Tomtebodavägen 23a in Stockholm, Sweden.
The final phase of the patient recruitment in the CONDUCT study
April 11, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that 197 patients, of the total 215 planned, have been enrolled to date in the CONDUCT study evaluating the drug candidate cobitolimod. The patient recruitment has varied significantly on a monthly basis, with between 6 and 19 patients enrolled, which makes it challenging to predict the remaining recruitment time. The company estimates that the patient recruitment will be completed during the month of June at the latest, which represents a delay compared to the previously communicated timeline. The company will announce when the last patient has been enrolled in the study and the top line results are expected to be available within 8-10 weeks thereafter.
April 5, 2019 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820, are hereby summoned to the Annual General Meeting on Monday May 6, 2019 at 5:00 p.m. (CET) at the company´s premises, Tomtebodavägen 23a in Stockholm, Sweden. Registration for the meeting begins at 4:30 p.m.
April 2, 2019 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2018, which is earlier than indicated in the financial calendar. The Annual Report (in the Swedish language) is attached as a PDF and is available on the company’s website, http://www.indexpharma.com.
Continued focus on the patient recruitment for the CONDUCT study
Directed share issue strengthens the cash position ahead of the CONDUCT results
November 6, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced the composition of the Nomination Committee for the 2019 Annual General Meeting, which will be held on Monday May 6, 2019. The responsibility of the Nomination Committee is to present to the 2019 Annual General Meeting proposals regarding election of the Chairman of the Board and other members of the Board, fees and any other remuneration to the members of the Board as well as election and remuneration of the auditors.
October 23, 2018 – The board of directors of InDex Pharmaceuticals Holding AB (publ) (the “Company” or “InDex”) has, with support from the authorization granted by the annual general meeting on May 24, 2018, resolved on a directed share issue of 6,252,842 shares to a small group of investors. The subscription price is SEK 6.02 per share, corresponding to a discount in line with market conditions of 7.7 percent to the 5-day volume weighted average price and 1.3 percent to today’s closing price. InDex will receive proceeds of approximately SEK 37.5 million after transaction related costs for legal services and costs for registration and practical management.
October 19, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced the publication of a post-hoc analysis of COLLECT study data. COLLECT was a clinical study of the Toll-like receptor 9 (TLR9) agonist cobitolimod, a first-in-class treatment for patients with moderate to severe ulcerative colitis (UC). The paper, published in the October issue of the peer-reviewed journal Digestive and Liver Disease (DLD), presents the clinical effect of cobitolimod on patient-reported outcomes (PRO) defined endpoints and in different patient subgroups defined by disease activity or anti-TNFα therapy exposure.
Updated timeline for the top line results from the CONDUCT study
August 9, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced an updated timeline for patient recruitment in the ongoing phase IIb study CONDUCT with the drug candidate cobitolimod. Top line results from the study are now expected in the first half of 2019 instead of in the fourth quarter of 2018 as previously communicated.
May 31, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced that the company will present two posters at the Digestive Disease Week (DDW). DDW is the largest congress in the world within gastroenterology. The congress is held in Washington DC, US on June 2-5, 2018.
May 24, 2018 – The Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) took place on Thursday, May 24, 2018 in the company´s premises at Tomtebodavägen 23a in Stockholm, Sweden.
Novel formulation for oral administration of cobitolimod
May 4, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced that it has developed a novel formulation of its lead drug candidate cobitolimod for oral administration, with targeted delivery to the lower part of the gastrointestinal tract. The oral formulation of cobitolimod is a potential follow-on product to the topical formulation, which is currently being investigated in the CONDUCT study – a phase IIb dose optimisation study in moderate to severe active ulcerative colitis.
April 24, 2018 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2017. The Annual Report (in the Swedish language) is attached as a PDF and is available on the company’s website, http://www.indexpharma.com.
April 23, 2018 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820, are hereby summoned to the Annual General Meeting on May 24, 2018 at 5:00 p.m. (CET) at the company´s premises, Tomtebodavägen 23a in Stockholm, Sweden. Registration for the meeting begins at 4:30 p.m.
April 12, 2018 – InDex Pharmaceuticals Holding AB (publ) (”InDex”) today announced the agenda for its Capital Markets Day that will take place in Stockholm on Wednesday April 25, 2018, for investors, analysts and media.
Mars 28, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod will be issued by the Japan Patent Office. The patent provides additional protection for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy, wherein cobitolimod is not administered in combination with corticosteroid or glucocorticosteroid.
March 26, 2018 – InDex Pharmaceuticals Holding AB (publ) (”InDex”) today announced that the company will host a Capital Markets Day in Stockholm on Wednesday April 25, 2018 for investors, analysts and media.
Deepened understanding of cobitolimod’s mechanism of action
February 13, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced that the recently reported new mechanism of action data for the drug candidate cobitolimod has been selected for an oral presentation at the 13th congress of the European Crohn’s and Colitis Organisation (ECCO).
December 1, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced new scientific data on the mechanism of action of cobitolimod, the company’s lead drug candidate. The findings show that cobitolimod can modulate the immune system in ulcerative colitis by balancing the mucosal Th17/Treg cell response.
Strengthened patent protection for cobitolimod
November 16, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced the composition of the Nomination Committee for the 2018 Annual General Meeting, which will be held on Thursday May 24, 2018. The responsibility of the Nomination Committee is to present to the 2018 Annual General Meeting proposals regarding election of the Chairman of the Board and other members of the Board, fees and any other remuneration to the members of the Board as well as election and remuneration of the auditor.
October 26, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that the company will present a poster at the United European Gastroenterology Week (UEGW). UEGW is the largest scientific meeting for gastroenterologists in Europe. The congress is held in Barcelona, Spain on October 28 – November 1, 2017.
October 12, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod will be issued by the United States Patent and Trademark Office (USPTO). The patent provides additional protection for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy, wherein cobitolimod is not administered in combination with corticosteroid or glucocorticosteroid.
September 13, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the Japan Patent Office. The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy.
First patient enrolled in the CONDUCT study
August 9, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that the US Food and Drug Administration (FDA) has granted orphan-drug designation for the drug candidate cobitolimod for treatment of ulcerative colitis in pediatric patients.
July 6, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the European Patent Office. The patent provides additional protection for the use of cobitolimod for the treatment of inflammatory diseases.
June 21, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that the first patient has been enrolled in the clinical study CONDUCT – a phase IIb dose optimisation study with the drug candidate cobitolimod. Cobitolimod is a first in class immunotherapeutic, which is being developed for the treatment of moderate to severe active ulcerative colitis.
May 30, 2017 – The Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) took place on Tuesday, May 30, 2017 in the company´s premises at Tomtebodavägen 23a in Stockholm, Sweden.
The CONDUCT study starts. Period January – March 2017. Revenues amounted to SEK 0.0 (0.0) million. Operating result amounted to SEK –22.1 (–6.9) million. Result after tax amounted to SEK –22.0 (–7.1) million, corresponding to SEK –0.35 per share (–0.23) before and after dilution
May 5, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that the company will present two posters at the Digestive Disease Week (DDW). DDW is the largest congress in the world within gastroenterology. The congress is held in Chicago, US on May 6-9, 2017.
April 27, 2017 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820, are hereby summoned to the Annual General Meeting on Tuesday, May 30, 2017 at 5:00 p.m. (CET) at the company´s premises, Tomtebodavägen 23a in Stockholm, Sweden. Registration for the meeting begins at 4:30 p.m.
InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2016. The Annual Report (in the Swedish language) is attached as a PDF and is available on the company’s website.
March 22, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that the company hosted a well attended investigators’ meeting for the CONDUCT study on March 20-21, 2017 in Stockholm. CONDUCT is a phase IIb dose optimisation study with the drug candidate cobitolimod for the treatment of moderate to severe active ulcerative colitis.
March 14, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that a patent covering 19 compounds from the company’s DIMS platform has been granted by the United States Patent and Trademark Office (USPTO).
March 8, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that the company has appointed Johan Giléus as new Chief Financial Officer (CFO) from May 1, 2017.
Focus on the final preparations of the CONDUCT study
February 1, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that the company has entered an agreement for services with the global contract research organization (CRO) PAREXEL for the implementation of the CONDUCT study. CONDUCT is a phase IIb dose optimisation study with the drug candidate cobitolimod for the treatment of moderate to severe active ulcerative colitis.
January 23, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that the company will have two posters at the 12th congress of the European Crohn’s and Colitis Organisation (ECCO). The ECCO congress is the largest congress in the world with a specific focus on inflammatory bowel disease (IBD). The congress is held in Barcelona, Spain on February 15-18, 2017.
Initial public offering and listing on Nasdaq First North Stockholm Period July – September 2016 Revenues amounted to MSEK 0.0 (0.0) Operating result amounted to MSEK -6.6 (-7.5) Result after…
November 3, 2016 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod will be granted by the United States Patent and Trademark Office (USPTO). The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy.
October 18, 2016 – Additional analyses of data from COLLECT – a clinical study of InDex Pharmaceuticals Holding AB’s (publ) lead drug candidate cobitolimod for the treatment of moderate to severe active ulcerative colitis – was orally presented and met with great interest at the United European Gastroenterology Week (UEGW) 2016 in Vienna.
October 10, 2016 – InDex Pharmaceuticals Holding AB (publ) announced today that results of additional analyses of data from COLLECT – a clinical study of its lead drug candidate cobitolimod for the treatment of moderate to severe active ulcerative colitis – will be presented orally and as a poster during the United European Gastroenterology Week (UEGW) October 15 – 19, 2016 in Vienna.
October 6, 2016 – InDex Pharmaceuticals Holding AB (publ) has met the requirements for listing on Nasdaq First North Stockholm and the marketplace has now given its formal approval to the company. First day of trading in the share is Tuesday, October 11, 2016. The share will be traded under the ticker INDEX and with the ISIN code SE0008966295.
THIS PRESS RELEASE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO USA, AUSTRALIA, CANADA, JAPAN OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE ILLEGAL.
THIS PRESS RELEASE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO USA, AUSTRALIA, CANADA, JAPAN OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE ILLEGAL.
THIS PRESS RELEASE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO USA, AUSTRALIA, CANADA, JAPAN OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE ILLEGAL.
THIS PRESS RELEASE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO USA, AUSTRALIA, CANADA, JAPAN OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE ILLEGAL.
THIS PRESS RELEASE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO USA, AUSTRALIA, CANADA, JAPAN OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE ILLEGAL.
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL
August 19, 2016 – The Board of InDex Pharmaceuticals today announced its intention to proceed with an Initial Public Offering of the drug development company on Nasdaq First North during the autumn. A new share issue in order to raise capital for the development of the company’s lead drug candidate – cobitolimod – is planned in connection with the listing.
July 13, 2016 – InDex Pharmaceuticals AB today announced the publication of the results from COLLECT, a clinical study of the Toll-like receptor 9 (TLR9) agonist cobitolimod as a first-in-class treatment for patients with moderate to severe ulcerative colitis (UC). The paper, published in the peer-reviewed Journal of Crohns and Colitis (JCC), supports the potential of cobitolimod as a novel treatment for moderate to severe active ulcerative colitis.
May 23, 2016 – InDex Pharmaceuticals AB today announced it has been granted 1.825 million SEK from Sweden´s innovation agency Vinnova to develop new, more effective and safer treatments for inflammatory diseases. Of 535 applications and 84 funded projects, InDex received one of the largest grants.
March 7, 2016 – InDex Pharmaceuticals AB today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a phase IIb study with its lead drug candidate cobitolimod (Kappaproct®) in patients with moderate to severe ulcerative colitis (UC).
February 10, 2016 – InDex Pharmaceuticals AB today announced that the World Health Organization (WHO) has recommended cobitolimod as the International Nonproprietary Name (INN) for Index´s lead drug candidate Kappaproct®, which is a first-in-class Toll-like receptor (TLR) 9 agonist in late-stage clinical development for moderate to severe ulcerative colitis.
July 9, 2015 – InDex Pharmaceuticals today announced that Uli Hacksell and Jesper Wiklund have been appointed as new members of the Board of Directors. Professor Hacksell and Mr Wiklund together bring to InDex over 40 years of senior management experience from the life sciences industry in drug development, commercial operations, and business development.
June 30, 2015 – InDex Pharmaceuticals today announced the termination of a license agreement with Almirall S.A. relating to the drug candidate Kappaproct® for the treatment of ulcerative colitis. Under the agreement, which was signed in March 2014, Almirall licensed exclusive rights to Kappaproct® for the European market. Upon termination of the agreement, InDex regains all worldwide development and commercialization rights for Kappaproct®, which is in late-stage clinical development.
February 5th, 2015 – InDex Pharmaceuticals today announced that the Board of Directors has named Peter Zerhouni as new CEO. Peter Zerhouni comes from a position as CEO at Diamyd Medical AB where he has been instrumental in bringing the company’s business and clinical trials forward. He will succeed Jesper Wiklund, who has led the company since 2011.
February 3rd, 2015 – InDex Pharmaceuticals today announced that results from COLLECT, a clinical study of the toll-like receptor 9 (TLR9) agonist Kappaproct as an add-on therapy for patients with moderate to severe, chronic active Ulcerative Colitis, will be subject to an oral presentation at the 10th Congress of the European Crohn’s and Colitis Organisation (ECCO). The congress is to be held in Barcelona, Spain on February 18-21, 2015.
June 27, 2014 – InDex Pharmaceuticals today reported top-line results from the double blind, placebo-controlled clinical study COLLECT. The aim of the COLLECT study was to investigate the therapeutic potential of the Toll-like receptor 9 agonist Kappaproct as an add-on therapy for patients with moderate to severe, chronic active Ulcerative Colitis.
Patients treated with Kappaproct showed statistically significant improvement on symptomatic remission (blood in stool, number of stools), registration remission (clinical remission with concurrent endoscopic remission) and the rate of colectomy. The rate of clinical remission (Rachmilewitz Index) was high in both the Kappaproct and the control group and no statistically significant difference was observed on this measure. Kappaproct was well tolerated and no safety signals compared to the standard of care treatment group were evident.
April 1st, 2014 InDex Pharmaceuticals and Almirall announced today that they have signed a license agreement for the European marketing rights to the drug candidate Kappaproct. Under the terms of…
InDex Pharmaceuticals today announced the successful closing of a USD 20 million / EUR 15 million new rights issue. NeoMed led the oversubscribed financing round while current shareholders participated with 75% of the invested capital.
Stockholm, April 8, 2013 – InDex Pharmaceuticals today announced the completion of patient enrollment for its Phase III COLLECT study of Kappaproct. The multinational, randomized, double- blind,…
Stockholm, October 24, 2012 – InDex Pharmaceuticals today announced that it has been granted a Japanese patent by the Japan Patent Office (JPO). The patent provides protection for the use of…
– Novel patent for Phase III lead drug candidate filed in the EU, US – Stockholm, August 30, 2012 – InDex Pharmaceuticals today announced the filing of a new patent with the United States Patent…
– InDex Pharmaceuticals reports positive clinical data in peer-reviewed journal Inflammatory Bowel Diseases – Stockholm, June 19, 2012 – InDex Pharmaceuticals today announced the publication of…
Former Lundbeck Executive Brings Strong Commercial Experience and Extensive Pharmaceutical Industry Network Stockholm, May 29, 2012 – InDex Pharmaceuticals today announced that Stig Løkke Pedersen…
Stockholm, April 26, 2012 – InDex Pharmaceuticals today announced that it has been granted a patent by the United States Patent and Trademark Office (USPTO). The patent provides additional…
InDex Pharmaceuticals Names Pernilla Sandwall Head of Clinical Operations and Thomas Knittel Chief Medical Officer Stockholm, April 11, 2012 – InDex Pharmaceuticals today announced two additions…
Personalized treatment option for patients with refractory ulcerative colitis Stockholm, March 20, 2012 – InDex Pharmaceuticals today announced the development of a companion diagnostic test for…
TLR9 Agonist for the Treatment of Chronic, Active, Treatment-Refractory Ulcerative Colitis Stockholm, March 6, 2012 – InDex Pharmaceuticals today announced the start of the COLLECT trial, a European…
Jesper Wiklund has been appointed Chief Executive Officer of InDex Pharmaceuticals AB (InDex) as of September 1st, 2011. He will bring 17 years of international commercial experience in the…
Industrifonden invests MSEK 40 and becomes a new shareholder in InDex
Pharmaceuticals, which develops Kappaproct – a drug for treatment of severe
inflammatory bowel disease. Current shareholders, including SEB Venture Capital,
invest an additional MSEK 35. The financing will in large be used to conduct a clinical
phase III trial using Kappaproct with the aim of obtaining market approval.
Stockholms läns landsting has as the first health care district in Sweden decided to
introduce DiBiCol on the list of reimbursed diagnostic tests. Approximately 15 000 out of a 1.5 million…
InDex Pharmaceuticals today announced that the first patent concerning the diagnostic test DiBiCol has been granted in Japan. With DiBiCol, the new and unique PCR-based test, inflammatory bowel…
Efficacy Demonstrated One Week after Single Dose Treatment The Swedish biopharmaceutical company InDex Pharmaceuticals AB today announced it has successfully concluded a clinical phase II proof of…
InDex Pharmaceuticals today announced that the last patient has now been recruited to
its clinical Phase II study of Kappaproct, for treating steroid resistant/dependent patients
with ulcerative…
InDex Pharmaceuticals has filed five more patents that will further strengthen its
extensive portfolio of proprietary intellectual assets. “We have complemented our IP assets with some important…